Miragen Therapeutics (MGEN) Is Now Covered By Oppenheimer. What can We Expect?

January 13, 2018 - By Darrin Black

 Miragen Therapeutics (MGEN) Is Now Covered By Oppenheimer. What can We Expect?

Why Has Oppenheimer Given Miragen Therapeutics (MGEN) a $13 Price Target

Oppenheimer began its coverage for Miragen Therapeutics (MGEN), this morning Friday, 12 January. Investment firm found the stock of MGEN quite attractive and now has a TP of $13 with a key “Outperform” rating.

Miragen Therapeutics, Inc. (NASDAQ:MGEN) Ratings Coverage

Among 6 analysts covering Miragen Therapeutics (MGEN), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Miragen Therapeutics has $19.0 highest and $13.0 lowest target. $15.75’s average target is 76.77% above currents $8.91 stock price. Miragen Therapeutics had 9 analyst reports since February 21, 2017 according to SRatingsIntel. Wedbush maintained the shares of MGEN in report on Friday, December 1 with “Buy” rating. Wedbush initiated Miragen Therapeutics, Inc. (NASDAQ:MGEN) on Tuesday, February 21 with “Outperform” rating. The company was maintained on Monday, August 14 by Chardan Capital Markets. Wedbush maintained the stock with “Buy” rating in Friday, August 18 report. The rating was initiated by Oppenheimer on Thursday, January 11 with “Buy”. The stock has “Buy” rating by Wedbush on Monday, October 16.

The stock increased 4.09% or $0.35 during the last trading session, reaching $8.91. About 140,851 shares traded. Miragen Therapeutics, Inc. (MGEN) has 0.00% since January 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts await Miragen Therapeutics, Inc. (NASDAQ:MGEN) to report earnings on March, 23. After $-0.27 actual EPS reported by Miragen Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 7.41 % negative EPS growth.

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. The company has market cap of $198.78 million. The Company’s two lead product candidates, MRG-106 and MRG-201 are in Phase 1 clinical trials. It currently has negative earnings. The companyÂ’s clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in various blood cancers.

More notable recent Miragen Therapeutics, Inc. (NASDAQ:MGEN) news were published by: Seekingalpha.com which released: “miRagen Therapeutics’ (MGEN) CEO William Marshall on Q3 2017 Results …” on November 10, 2017, also Globenewswire.com with their article: “miRagen Therapeutics Presents New Interim Clinical Data Expanding on Previous …” published on December 11, 2017, Benzinga.com published: “Miragen Could Surpass $1 Billion In Revenue In 2025, Says Biotech Analyst” on January 12, 2018. More interesting news about Miragen Therapeutics, Inc. (NASDAQ:MGEN) were released by: Globenewswire.com and their article: “miRagen Therapeutics to Present at the Cantor Fitzgerald Global Healthcare …” published on September 01, 2017 as well as Globenewswire.com‘s news article titled: “miRagen Therapeutics to Announce Third Quarter 2017 Financial Results and Host …” with publication date: November 01, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.